Mark A. Emalfarb
Known title: President and CEOCIK: 0001328287
Associated companies
Transaction History
| DYAI | ▲ Buy | Grant | 102,609 | $0 | 1/2/2026 | View on chart |
| DYAI | ▲ Buy | Grant | 73,111 | $0 | 1/2/2025 | View on chart |
| DYAI | ▲ Buy | Grant | 124,454 | $0 | 3/13/2024 | View on chart |
| DYAI | ▲ Buy | Grant | 138,478 | $191K | 1/3/2023 | View on chart |
| DYAI | ▼ Sell | Open Market | 28,767 | $118K | 12/23/2021 | View on chart |
| DYAI | ▲ Buy | Option Exercise | 150,000 | $244K | 12/23/2021 | View on chart |
| DYAI | ▼ Sell | Open Market | 35,649 | $147K | 12/22/2021 | View on chart |
| DYAI | ▼ Sell | Open Market | 26,486 | $115K | 12/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Dyadic International Included in After-Market Movers List
Dyadic International was featured in a Benzinga report highlighting health care stocks that moved during Monday's after-market session. The stock currently trades well below its analyst average target price, with a 52-week range spanning from $0.34 to $1.60. This inclusion reflects recent trading activity rather than a specific company announcement.
Dyadic International Included in After-Market Movers List. Dyadic International was featured in a Benzinga report highlighting health care stocks that moved during Monday's after-market session. The stock currently trades well below its analyst average target price, with a 52-week range spanning from $0.34 to $1.60. This inclusion reflects recent trading activity rather than a specific company announcement.